GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains ...

Researchers have identified a new potential weapon against Alzheimer’s: blocking a protein called PTP1B. In mice, this approach boosted memory and helped brain immune cells clear harmful plaque ...

A total of 116,022 people died from Alzheimer’s disease in 2024, an 134.1% increase from the 49,558 deaths reported in 2000.

The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...

Cognitive decline in Alzheimer's disease differs substantially from one person to the next and is not well predicted by ...

Health and Human Services Secretary Robert F. Kennedy Jr. recently announced that “it is regulatory malpractice that we don’t ...

It’s “a move away from a one-size-fits-all framework for Alzheimer’s disease.” ...

A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein ...